Preoperative Differentiation of HER2-Zero and HER2-Low from HER2-Positive Invasive Ductal Breast Cancers Using BI-RADS MRI Features and Machine Learning Modeling.

Journal: Journal of magnetic resonance imaging : JMRI
PMID:

Abstract

BACKGROUND: Accurate determination of human epidermal growth factor receptor 2 (HER2) is important for choosing optimal HER2 targeting treatment strategies. HER2-low is currently considered HER2-negative, but patients may be eligible to receive new anti-HER2 drug conjugates.

Authors

  • Jiejie Zhou
    Department of Radiology, First Affiliate Hospital of Wenzhou Medical University, Wenzhou, China.
  • Yang Zhang
    Innovative Institute of Chinese Medicine and Pharmacy, Academy for Interdiscipline, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Haiwei Miao
    Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, PR China.
  • Ga Young Yoon
    Department of Radiological Sciences, University of California, Irvine, California, USA.
  • Jinhao Wang
  • Yezhi Lin
    Information Technology Center, First Affiliate Hospital of Wenzhou Medical University, Wenzhou, China.
  • Hailing Wang
    Guangxi Normal University, Guilin, China.
  • Yan-Lin Liu
    Department of Radiological Sciences, University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA.
  • Jeon-Hor Chen
    Department of Radiology, E-Da Hospital and I-Shou University, Kaohsiung 82445, Taiwan and Tu and Yuen Center for Functional Onco-Imaging and Department of Radiological Science, University of California, Irvine, California 92697.
  • Zhifang Pan
    Information Technology Center, Wenzhou Medical University, 325035, China.
  • Min-Ying Su
    Department of Radiological Sciences, University of California, Irvine, CA 92697, USA.
  • Meihao Wang
    Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, PR China.